You are here:

Forthcoming Submission: sofosbuvir / velpatasvir (Epclusa)

Indication: The licensed indication for SOF/VEL covers chronic HCV infection of any genotype (GT1–6) in patients without cirrhosis, those with compensated cirrhosis and those with decompensated cirrhosis. The current submission covers genotypes 1 and 4 patients without or with compensated cirrhosis. SOF/VEL has received prior approval from the SMC for the treatment of CHC GT2, 3, 5 and 6 patients without or with compensated cirrhosis as well as patients with decompensated cirrhosis irrespective of CHC genotype (2, 3).

Drug Details

Drug Name: sofosbuvir / velpatasvir (Epclusa)
Drug Manufacturer: Gilead Sciences Ltd
BNF Category:
Submission type: Resubmission
Patient Interest Group
Submission Deadline:
SMC Meeting Date: 6/03/2018
Advice Due: 9/04/2018